Boston Scientific Acquires Baylis Medical

February 15, 2022—Boston Scientific Corporation announced that it has closed on its acquisition of Baylis Medical Company, Inc. for an upfront payment of $1.75 billion. Baylis Medical offers advanced transseptal access solutions as well as guidewires, sheaths, and dilators used to support catheter-based left-heart procedures. With this acquisition, Boston Scientific will expand its electrophysiology and structural heart portfolios to include Baylis Medical’s radiofrequency NRG and VersaCross transseptal platforms. The two companies’ entrance into a definitive agreement was previously reported in October 2021.

In the press release, Joe Fitzgerald, Executive Vice President, and President, Cardiology, Boston Scientific, stated, “The close of this acquisition allows Boston Scientific to integrate the Baylis platforms with our existing electrophysiology and structural heart offerings, further strengthening our position within the highest growth cardiology markets. We are now the only company to pair a comprehensive access portfolio with existing left-heart therapies such as left atrial appendage closure and atrial fibrillation ablation, providing physicians with a complete toolbox to treat patients with safety, efficacy and efficiency.”

According to the announcement, the transaction is expected to be approximately one cent accretive to adjusted earnings per share in 2022, and increasingly accretive thereafter. More information about the transaction is available on the Events and Presentations section of the Boston Scientific investor relations website.